These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26174900)

  • 41. Anti-D immunoglobulin-induced prolonged intravascular hemolysis and neutropenia.
    Alioglu B; Avci Z; Ozyurek E; Ozbek N
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):636-9. PubMed ID: 17805040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations.
    Sakem B; Matozan K; Nydegger UE; Weigel G; Griesmacher A; Risch L
    Isr Med Assoc J; 2013 Oct; 15(10):617-21. PubMed ID: 24266088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Necrotizing enterocolitis in a newborn following intravenous immunoglobulin treatment for haemolytic disease.
    Kara S; Ulu-ozkan H; Yilmaz Y; Arikan FI; Dilmen U; Bilge YD
    J Coll Physicians Surg Pak; 2013 Aug; 23(8):598-600. PubMed ID: 23930883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
    Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
    J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production.
    Tjon AS; van Gent R; Jaadar H; Martin van Hagen P; Mancham S; van der Laan LJ; te Boekhorst PA; Metselaar HJ; Kwekkeboom J
    J Immunol; 2014 Jun; 192(12):5625-34. PubMed ID: 24808368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
    Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
    Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Serum levels of interleukin-6 and interleukin-10 in patients with multiple sclerosis during intravenous immunoglobulin infusion].
    Kazibutowska Z; Motta E; Huć M; Strzała-Orzeł M; Woźnik G
    Wiad Lek; 2006; 59(9-10):626-9. PubMed ID: 17338118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade.
    Svetlicky N; Ortega-Hernandez OD; Mouthon L; Guillevin L; Thiesen HJ; Altman A; Kravitz MS; Blank M; Shoenfeld Y
    J Clin Immunol; 2013 Jan; 33 Suppl 1():S27-32. PubMed ID: 23229779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study.
    Aubin F; Porcher R; Jeanmougin M; Léonard F; Bedane C; Moreau A; Schmutz JL; Marguery MC; Adamski H; Viguier M;
    J Am Acad Dermatol; 2014 Nov; 71(5):948-953.e1. PubMed ID: 25135650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?
    Elovaara I; Hietaharju A
    Acta Neurol Scand; 2010 Nov; 122(5):309-15. PubMed ID: 20085560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
    Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
    Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravenous immunoglobulin a natural regulator of immunity and inflammation.
    Jordan SC; Toyoda M; Vo AA
    Transplantation; 2009 Jul; 88(1):1-6. PubMed ID: 19584672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin).
    Ruiz de Souza V; Carreno MP; Kaveri SV; Ledur A; Sadeghi H; Cavaillon JM; Kazatchkine MD; Haeffner-Cavaillon N
    Eur J Immunol; 1995 May; 25(5):1267-73. PubMed ID: 7774630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous immune globulin in neonatal immune hemolytic disease: does it reduce hemolysis?
    Hammerman C; Vreman HJ; Kaplan M; Stevenson DK
    Acta Paediatr; 1996 Nov; 85(11):1351-3. PubMed ID: 8955465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome.
    Wakim M; Alazard M; Yajima A; Speights D; Saxon A; Stiehm ER
    Ann Allergy Asthma Immunol; 1998 Aug; 81(2):153-8. PubMed ID: 9723561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Exfoliative dermatitis as a side effect of intravenous immunoglobulin treatment].
    Markvardsen LH; Jakobsen J
    Ugeskr Laeger; 2011 Oct; 173(43):2725-6. PubMed ID: 22027232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.